Danaher ( DHR ) Just Overtook the 200-Day Moving Average
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 1.23% on an annualized basis producing an average annual return of 13.19%. Currently, Danaher has a market capitalization of $149.65 billion.
iA Global Buys the Dip in Danaher's Stock Price
On Aug. 5, iA Global Asset Management Inc. disclosed buying 301,028 shares of Danaher ( NYSE:DHR ) , valued at approximately $58.43 million in Q2 2025.The investment firm bought 301,028 shares for $58.43 million in the quarter ended June 30.The transaction represented 0.88% of iA Global Asset ...
Why Envista ( NVST ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS or DHR: Which Is the Better Value Stock Right Now?
CVS vs. DHR: Which Stock Is the Better Value Option?
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veralto ( VLTO ) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Danaher Stock Closes Near Day's High After Key Trading Signal - Danaher ( NYSE:DHR )
DHR reverses early down move after Alert Danaher Corp. DHR experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
Markel's Q2 Earnings Surpass Estimates, Premiums Rise Y/Y
MKL tops Q2 earnings and revenue estimates, but profits dip as rising expenses weigh on margins.
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive.
International Markets and Danaher ( DHR ) : A Deep Dive for Investors
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 1.09% on an annualized basis producing an average annual return of 12.78%. Currently, Danaher has a market capitalization of $147.13 billion.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS or DHR: Which Is the Better Value Stock Right Now?
CVS vs. DHR: Which Stock Is the Better Value Option?
Here's Why Danaher ( DHR ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Danaher Raises 2025 Earnings Outlook
Danaher ( NYSE:DHR ) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free cash flow hit $1.1 billion, and management raised full-year adjusted diluted net EPS guidance to ...
Danaher Beats Q2 Revenue, EPS Forecasts
Global science and technology innovator Danaher ( NYSE:DHR ) reported second quarter 2025 results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue of $5.94 billion came in above the $5.84 billion estimate, and adjusted EPS reached $1.80 versus the $1.64 analysts ...
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline - Danaher ( NYSE:DHR )
Danaher posted Q2 sales of $5.94 billion and EPS of $1.80, beating estimates of $5.84 billion and $1.64. Biotech sales rose to $1.85 billion with 6% core growth; profit margin hit 27.3% vs. 25.5% expected.
Danaher ( DHR ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 22, 2025 at 8:00 a.m. ETPresident and Chief Executive Officer - Rainer BlairContinue reading ...
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Danaher ( DHR ) Q2 Earnings and Revenues Top Estimates
Danaher (DHR) delivered earnings and revenue surprises of +9.76% and +1.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Danaher ( DHR ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Danaher (DHR) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's How Much a $1000 Investment in Agilent Technologies Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
What Does the Market Think About Danaher? - Danaher ( NYSE:DHR )
Danaher's DHR short percent of float has risen 4.27% since its last report. The company recently reported that it has 7.75 million shares sold short, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their ...
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Abbott Laboratories ( NYSE:ABT ) , Danaher ( NYSE:DHR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group slashed Danaher Corporation DHR price target from $230 to $226.
Here's How Much $1000 Invested In Danaher 10 Years Ago Would Be Worth Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 1.65% on an annualized basis producing an average annual return of 13.14%. Currently, Danaher has a market capitalization of $143.92 billion.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health ( CVS Quick QuoteCVS - ) and Danaher ( DHR Quick QuoteDHR - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Workday Has Cramer Worried, Is Applied Digital 'A Good Spec'? - Applied Digital ( NASDAQ:APLD ) , AST SpaceMobile ( NASDAQ:ASTS )
"This stock has been such a disappointment for me," Cramer on Danaher. "I'm going to go with the flow and tell you it's time to sell," Cramer on DocuSign. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.
Here's How Much You'd Have If You Invested $1000 in Agilent Technologies a Decade Ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's How Much $1000 Invested In Danaher 10 Years Ago Would Be Worth Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 2.59% on an annualized basis producing an average annual return of 13.67%. Currently, Danaher has a market capitalization of $143.13 billion.
CVS vs. DHR: Which Stock Should Value Investors Buy Now?
CVS vs. DHR: Which Stock Is the Better Value Option?
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
How Do Investors Really Feel About Danaher? - Danaher ( NYSE:DHR )
Danaher's DHR short percent of float has fallen 4.1% since its last report. The company recently reported that it has 7.45 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.81 days to cover their ...
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 1.68% on an annualized basis producing an average annual return of 12.54%. Currently, Danaher has a market capitalization of $135.98 billion.
Cardiac Marker Market Size Projected to Reach USD 28.27 billion by 2031 at a 13.2% CAGR | The Insight Partners
US & Canada, May 28, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the cardiac marker market is witnessing significant growth owing to the rising prevalence of Cardiovascular diseases ( CVDs ) and growing technological advancements in diagnostic ...
It's Unofficially Summer. Time to Get Outside, and Talk With Decking Expert Trex CEO Bryan Fairbanks
In this podcast, Motley Fool host Dylan Lewis and analysts Jason Moser and Bill Mann discuss:Motley Fool analysts Andy Cross and Sanmeet Deo caught up with Trex CEO Bryan Fairbanks to talk about the war on wood decks, how the company is handling tariffs, and why he expects business to boom as ...
CVS or DHR: Which Is the Better Value Stock Right Now?
CVS vs. DHR: Which Stock Is the Better Value Option?
Here's Why Investors Should Consider Retaining Danaher Stock Now
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
Market Whales and Their Recent Bets on DHR Options - Danaher ( NYSE:DHR )
High-rolling investors have positioned themselves bearish on Danaher DHR, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
P/E Ratio Insights for Danaher - Danaher ( NYSE:DHR )
Looking into the current session, Danaher Inc. DHR shares are trading at $197.77, after a 0.69% spike. Moreover, over the past month, the stock increased by 2.97%, but in the past year, decreased by 25.98%.
Digital PCR and Real-Time PCR Market Size Worth USD 17.54 billion by 2031 at 9.1% CAGR | The Insight Partners
US & Canada, May 19, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the global digital PCR and real-time PCR market is witnessing substantial growth with the surging incidence of genetic and infectious diseases and rising investments in gene ...
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion.
CVS vs. DHR: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health ( CVS Quick QuoteCVS - ) or Danaher ( DHR Quick QuoteDHR - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Point of Care Diagnostics Market Size to Reach $82.95 Bn by 2028 Globally, at 12.7% CAGR: The Insight Partners
US & Canada, April 28, 2025 ( GLOBE NEWSWIRE ) -- As per a new, comprehensive report from The Insight Partners, the Point of Care Diagnostics Market is experiencing significant growth owing to increasing incidences of infectious diseases.
Market Whales and Their Recent Bets on DHR Options - Danaher ( NYSE:DHR )
Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher. Looking at options history for Danaher DHR we detected 16 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 56% ...
$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today - Danaher ( NYSE:DHR )
Danaher DHR has outperformed the market over the past 10 years by 3.44% on an annualized basis producing an average annual return of 13.45%. Currently, Danaher has a market capitalization of $140.63 billion.
How Is The Market Feeling About Danaher? - Danaher ( NYSE:DHR )
Danaher's DHR short percent of float has fallen 22.13% since its last report. The company recently reported that it has 6.03 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.77 days to cover their ...
